Skip to main content
Top
Published in: BMC Cancer 1/2023

Open Access 01-12-2023 | Ovarian Cancer | Research

Functional analyses of rare germline BRCA1 variants by transcriptional activation and homologous recombination repair assays

Authors: Nicola Bassi, Henrikke Nilsen Hovland, Kashif Rasheed, Elisabeth Jarhelle, Nikara Pedersen, Eunice Kabanyana Mchaina, Sara Marie Engelsvold Bakkan, Nina Iversen, Hildegunn Høberg-Vetti, Bjørn Ivar Haukanes, Per Morten Knappskog, Ingvild Aukrust, Elisabet Ognedal, Marijke Van Ghelue

Published in: BMC Cancer | Issue 1/2023

Login to get access

Abstract

Background

Damaging alterations in the BRCA1 gene have been extensively described as one of the main causes of hereditary breast and ovarian cancer (HBOC). BRCA1 alterations can lead to impaired homologous recombination repair (HRR) of double-stranded DNA breaks, a process which involves the RING, BRCT and coiled-coil domains of the BRCA1 protein. In addition, the BRCA1 protein is involved in transcriptional activation (TA) of several genes through its C-terminal BRCT domain.

Methods

In this study, we have investigated the effect on HRR and TA of 11 rare BRCA1 missense variants classified as variants of uncertain clinical significance (VUS), located within or in close proximity to the BRCT domain, with the aim of generating additional knowledge to guide the correct classification of these variants. The variants were selected from our previous study “BRCA1 Norway”, which is a collection of all BRCA1 variants detected at the four medical genetic departments in Norway.

Results

All variants, except one, showed a significantly reduced HRR activity compared to the wild type (WT) protein. Two of the variants (p.Ala1708Val and p.Trp1718Ser) also exhibited low TA activity similar to the pathogenic controls. The variant p.Trp1718Ser could be reclassified to likely pathogenic. However, for ten of the variants, the total strength of pathogenic evidence was not sufficient for reclassification according to the CanVIG-UK BRCA1/BRCA2 gene-specific guidelines for variant interpretation.

Conclusions

When including the newly achieved functional evidence with other available information, one VUS was reclassified to likely pathogenic. Eight of the investigated variants affected only one of the assessed activities of BRCA1, highlighting the importance of comparing results obtained from several functional assays to better understand the consequences of BRCA1 variants on protein function. This is especially important for multifunctional proteins such as BRCA1.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef Bray F, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.PubMedCrossRef
2.
go back to reference Golubeva VA, Nepomuceno TC, Monteiro ANA. Germline Missense Variants in BRCA1: New Trends and Challenges for Clinical Annotation. Cancers (Basel). 2019;11(4):522.PubMedPubMedCentralCrossRef Golubeva VA, Nepomuceno TC, Monteiro ANA. Germline Missense Variants in BRCA1: New Trends and Challenges for Clinical Annotation. Cancers (Basel). 2019;11(4):522.PubMedPubMedCentralCrossRef
3.
go back to reference Gelli E, et al. Usefulness and Limitations of Comprehensive Characterization of mRNA Splicing Profiles in the Definition of the Clinical Relevance of BRCA1/2 Variants of Uncertain Significance. Cancers (Basel). 2019;11(3):295.PubMedCrossRef Gelli E, et al. Usefulness and Limitations of Comprehensive Characterization of mRNA Splicing Profiles in the Definition of the Clinical Relevance of BRCA1/2 Variants of Uncertain Significance. Cancers (Basel). 2019;11(3):295.PubMedCrossRef
5.
go back to reference Olopade OI, Fackenthal JD. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007;7(12):937–48.PubMedCrossRef Olopade OI, Fackenthal JD. Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nat Rev Cancer. 2007;7(12):937–48.PubMedCrossRef
6.
go back to reference Kuchenbaecker KB, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402–16.PubMedCrossRef Kuchenbaecker KB, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402–16.PubMedCrossRef
7.
go back to reference Kuchenbaecker KB, et al. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017;109(7):djw302.PubMedPubMedCentralCrossRef Kuchenbaecker KB, et al. Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. J Natl Cancer Inst. 2017;109(7):djw302.PubMedPubMedCentralCrossRef
8.
go back to reference Safran M, et al. GeneCards Version 3: the human gene integrator. Database (Oxford). 2010;2010:baq020–baq020.PubMedCrossRef Safran M, et al. GeneCards Version 3: the human gene integrator. Database (Oxford). 2010;2010:baq020–baq020.PubMedCrossRef
9.
go back to reference Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2012;12(1):68–78.CrossRef Roy R, Chun J, Powell SN. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nat Rev Cancer. 2012;12(1):68–78.CrossRef
10.
go back to reference Venkitaraman AR. Cancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2. Science. 2014;343(6178):1470–5.PubMedCrossRef Venkitaraman AR. Cancer Suppression by the Chromosome Custodians, BRCA1 and BRCA2. Science. 2014;343(6178):1470–5.PubMedCrossRef
11.
12.
go back to reference Corso G, et al. BRCA1/2 germline missense mutations: a systematic review. Eur J Cancer Prev. 2018;27(3):279–86.PubMedCrossRef Corso G, et al. BRCA1/2 germline missense mutations: a systematic review. Eur J Cancer Prev. 2018;27(3):279–86.PubMedCrossRef
15.
go back to reference Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95(11):866–71.PubMedCrossRef Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95(11):866–71.PubMedCrossRef
16.
17.
18.
go back to reference Monteiro AN, August A, Hanafusa H. Evidence for a Transcriptional Activation Function of BRCA1 C-Terminal Region. Proc Natl Acad Sci U S A. 1996;93(24):13595–9.PubMedPubMedCentralCrossRef Monteiro AN, August A, Hanafusa H. Evidence for a Transcriptional Activation Function of BRCA1 C-Terminal Region. Proc Natl Acad Sci U S A. 1996;93(24):13595–9.PubMedPubMedCentralCrossRef
21.
go back to reference Hovland HN, et al. BRCA1 Norway: comparison of classification for BRCA1 germline variants detected in families with suspected hereditary breast and ovarian cancer between different laboratories. Fam Cancer. 2022;21(4):389–98.PubMedPubMedCentralCrossRef Hovland HN, et al. BRCA1 Norway: comparison of classification for BRCA1 germline variants detected in families with suspected hereditary breast and ovarian cancer between different laboratories. Fam Cancer. 2022;21(4):389–98.PubMedPubMedCentralCrossRef
22.
go back to reference Ransburgh DJ, et al. The effect of BRCA1 missense mutations on homology directed recombination. Cancer research (Chicago, Ill). 2010;70(3):988–95. Ransburgh DJ, et al. The effect of BRCA1 missense mutations on homology directed recombination. Cancer research (Chicago, Ill). 2010;70(3):988–95.
23.
go back to reference den Dunnen JT, et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Hum Mutat. 2016;37(6):564–9.CrossRef den Dunnen JT, et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update. Hum Mutat. 2016;37(6):564–9.CrossRef
24.
25.
go back to reference Garrett A, et al. Combining evidence for and against pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendations. J Med Genet. 2021;58(5):297–304.PubMedCrossRef Garrett A, et al. Combining evidence for and against pathogenicity for variants in cancer susceptibility genes: CanVIG-UK consensus recommendations. J Med Genet. 2021;58(5):297–304.PubMedCrossRef
26.
27.
go back to reference Glover JNM, Williams RS, Green R. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol. 2001;8(10):838–42.PubMedCrossRef Glover JNM, Williams RS, Green R. Crystal structure of the BRCT repeat region from the breast cancer-associated protein BRCA1. Nat Struct Biol. 2001;8(10):838–42.PubMedCrossRef
28.
go back to reference Williams RS, et al. Detection of Protein Folding Defects Caused by BRCA1-BRCT Truncation and Missense Mutations. J Biol Chem. 2003;278(52):53007–16.PubMedCrossRef Williams RS, et al. Detection of Protein Folding Defects Caused by BRCA1-BRCT Truncation and Missense Mutations. J Biol Chem. 2003;278(52):53007–16.PubMedCrossRef
29.
go back to reference Fernandes VC, et al. Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation. J Biol Chem. 2019;294(15):5980–92.PubMedPubMedCentralCrossRef Fernandes VC, et al. Impact of amino acid substitutions at secondary structures in the BRCT domains of the tumor suppressor BRCA1: Implications for clinical annotation. J Biol Chem. 2019;294(15):5980–92.PubMedPubMedCentralCrossRef
30.
go back to reference Nepomuceno TC, et al. Assessment of small in-frame indels and C-terminal nonsense variants of BRCA1 using a validated functional assay. Sci Rep. 2022;12(1):16203–16203.PubMedPubMedCentralCrossRef Nepomuceno TC, et al. Assessment of small in-frame indels and C-terminal nonsense variants of BRCA1 using a validated functional assay. Sci Rep. 2022;12(1):16203–16203.PubMedPubMedCentralCrossRef
31.
32.
go back to reference Lee MS, et al. Comprehensive Analysis of Missense Variations in the BRCT Domain of BRCA1 by Structural and Functional Assays. Cancer Res. 2010;70(12):4880–90.PubMedPubMedCentralCrossRef Lee MS, et al. Comprehensive Analysis of Missense Variations in the BRCT Domain of BRCA1 by Structural and Functional Assays. Cancer Res. 2010;70(12):4880–90.PubMedPubMedCentralCrossRef
33.
go back to reference Lovelock PK, et al. Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Res. 2007;9(6):R82–R82.PubMedPubMedCentralCrossRef Lovelock PK, et al. Identification of BRCA1 missense substitutions that confer partial functional activity: potential moderate risk variants? Breast Cancer Res. 2007;9(6):R82–R82.PubMedPubMedCentralCrossRef
34.
go back to reference Petitalot A, et al. Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of BRCA1 BRCT Variants on Cancer Risk. Mol Cancer Res. 2019;17(1):54–69.PubMedCrossRef Petitalot A, et al. Combining Homologous Recombination and Phosphopeptide-binding Data to Predict the Impact of BRCA1 BRCT Variants on Cancer Risk. Mol Cancer Res. 2019;17(1):54–69.PubMedCrossRef
36.
go back to reference Worley T, et al. A naturally occurring allele of BRCA1 coding for a temperature-sensitive mutant protein. Cancer Biol Ther. 2002;1(5):497.PubMedCrossRef Worley T, et al. A naturally occurring allele of BRCA1 coding for a temperature-sensitive mutant protein. Cancer Biol Ther. 2002;1(5):497.PubMedCrossRef
37.
go back to reference Carvalho MA, et al. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res. 2007;67(4):1494–501.PubMedPubMedCentralCrossRef Carvalho MA, et al. Determination of cancer risk associated with germ line BRCA1 missense variants by functional analysis. Cancer Res. 2007;67(4):1494–501.PubMedPubMedCentralCrossRef
39.
go back to reference Lu C, et al. Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun. 2015;6(1):10086.PubMedCrossRef Lu C, et al. Patterns and functional implications of rare germline variants across 12 cancer types. Nat Commun. 2015;6(1):10086.PubMedCrossRef
40.
go back to reference Ahlborn LB, et al. Splicing analysis of 14 BRCA1 missense variants classifies nine variants as pathogenic. Breast Cancer Res Treat. 2015;150(2):289–98.PubMedPubMedCentralCrossRef Ahlborn LB, et al. Splicing analysis of 14 BRCA1 missense variants classifies nine variants as pathogenic. Breast Cancer Res Treat. 2015;150(2):289–98.PubMedPubMedCentralCrossRef
41.
go back to reference Mirkovic N, et al. Structure-based assessment of missense mutations in human BRCA1: Implications for breast and ovarian cancer predisposition. Cancer Res. 2004;64(11):3790–7.PubMedCrossRef Mirkovic N, et al. Structure-based assessment of missense mutations in human BRCA1: Implications for breast and ovarian cancer predisposition. Cancer Res. 2004;64(11):3790–7.PubMedCrossRef
42.
go back to reference Glover JNM. Insights into the molecular basis of human hereditary breast cancer from studies of the BRCA1 BRCT domain. Fam Cancer. 2006;5(1):89–93.PubMedCrossRef Glover JNM. Insights into the molecular basis of human hereditary breast cancer from studies of the BRCA1 BRCT domain. Fam Cancer. 2006;5(1):89–93.PubMedCrossRef
43.
44.
go back to reference Blay P, et al. Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). BMC Cancer. 2013;13(1):243–243.PubMedPubMedCentralCrossRef Blay P, et al. Mutational analysis of BRCA1 and BRCA2 in hereditary breast and ovarian cancer families from Asturias (Northern Spain). BMC Cancer. 2013;13(1):243–243.PubMedPubMedCentralCrossRef
45.
go back to reference Wang B, et al. NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. Genes Dev. 2009;23(6):729–39.PubMedPubMedCentralCrossRef Wang B, et al. NBA1, a new player in the Brca1 A complex, is required for DNA damage resistance and checkpoint control. Genes Dev. 2009;23(6):729–39.PubMedPubMedCentralCrossRef
46.
go back to reference Coleman KA, Greenberg RA. The BRCA1-RAP80 Complex Regulates DNA Repair Mechanism Utilization by Restricting End Resection. J Biol Chem. 2011;286(15):13669–80.PubMedPubMedCentralCrossRef Coleman KA, Greenberg RA. The BRCA1-RAP80 Complex Regulates DNA Repair Mechanism Utilization by Restricting End Resection. J Biol Chem. 2011;286(15):13669–80.PubMedPubMedCentralCrossRef
48.
go back to reference Yu XC, Chen JJ. DNA Damage-Induced Cell Cycle Checkpoint Control Requires CtIP, a Phosphorylation-Dependent Binding Partner of BRCA1 C-Terminal Domains. Mol Cell Biol. 2004;24(21):9478–86.PubMedPubMedCentralCrossRef Yu XC, Chen JJ. DNA Damage-Induced Cell Cycle Checkpoint Control Requires CtIP, a Phosphorylation-Dependent Binding Partner of BRCA1 C-Terminal Domains. Mol Cell Biol. 2004;24(21):9478–86.PubMedPubMedCentralCrossRef
49.
go back to reference Chen L, et al. Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. J Biol Chem. 2008;283(12):7713–20.PubMedCrossRef Chen L, et al. Cell cycle-dependent complex formation of BRCA1.CtIP.MRN is important for DNA double-strand break repair. J Biol Chem. 2008;283(12):7713–20.PubMedCrossRef
50.
go back to reference Nakanishi M, et al. NFBD1/MDC1 Associates with p53 and Regulates Its Function at the Crossroad between Cell Survival and Death in Response to DNA Damage. J Biol Chem. 2007;282(31):22993–3004.PubMedCrossRef Nakanishi M, et al. NFBD1/MDC1 Associates with p53 and Regulates Its Function at the Crossroad between Cell Survival and Death in Response to DNA Damage. J Biol Chem. 2007;282(31):22993–3004.PubMedCrossRef
51.
go back to reference Rodriguez JA, Au WWY, Henderson BR. Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain. Exp Cell Res. 2004;293(1):14–21.PubMedCrossRef Rodriguez JA, Au WWY, Henderson BR. Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain. Exp Cell Res. 2004;293(1):14–21.PubMedCrossRef
52.
go back to reference Drikos I, Boutou E, Kastritis PL, Vorgias CE. BRCA1-BRCT mutations alter the subcellular localization of BRCA1 in vitro. Anticancer Res. 2021;41:2953–62.PubMedCrossRef Drikos I, Boutou E, Kastritis PL, Vorgias CE. BRCA1-BRCT mutations alter the subcellular localization of BRCA1 in vitro. Anticancer Res. 2021;41:2953–62.PubMedCrossRef
53.
go back to reference Bouwman P, et al. Functional categorization of BRCA1 variants of uncertain clinical significance in homologous recombination repair complementation assays. Clin Cancer Res. 2020;26(17):4559–68.PubMedCrossRef Bouwman P, et al. Functional categorization of BRCA1 variants of uncertain clinical significance in homologous recombination repair complementation assays. Clin Cancer Res. 2020;26(17):4559–68.PubMedCrossRef
54.
go back to reference Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.PubMedPubMedCentralCrossRef Richards S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24.PubMedPubMedCentralCrossRef
55.
go back to reference Starita LM, et al. A Multiplex Homology-Directed DNA Repair Assay Reveals the Impact of More Than 1,000 BRCA1 Missense Substitution Variants on Protein Function. Am J Hum Genet. 2018;103(4):498–508.PubMedPubMedCentralCrossRef Starita LM, et al. A Multiplex Homology-Directed DNA Repair Assay Reveals the Impact of More Than 1,000 BRCA1 Missense Substitution Variants on Protein Function. Am J Hum Genet. 2018;103(4):498–508.PubMedPubMedCentralCrossRef
56.
go back to reference Brnich SE, et al. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. Genome medicine. 2019;12(1):1–12. Brnich SE, et al. Recommendations for application of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant interpretation framework. Genome medicine. 2019;12(1):1–12.
58.
Metadata
Title
Functional analyses of rare germline BRCA1 variants by transcriptional activation and homologous recombination repair assays
Authors
Nicola Bassi
Henrikke Nilsen Hovland
Kashif Rasheed
Elisabeth Jarhelle
Nikara Pedersen
Eunice Kabanyana Mchaina
Sara Marie Engelsvold Bakkan
Nina Iversen
Hildegunn Høberg-Vetti
Bjørn Ivar Haukanes
Per Morten Knappskog
Ingvild Aukrust
Elisabet Ognedal
Marijke Van Ghelue
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2023
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-023-10790-w

Other articles of this Issue 1/2023

BMC Cancer 1/2023 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine